CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector under the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, reporting fiscal 2026 net sales of $6.7 billion with approximately 9,200 employees across roughly 25 countries and sales in about 95 markets. Its consumer-facing brands include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional division sells under the Purell, CloroxPro, and Clorox Healthcare labels. The breadth of the brand portfolio suggests a business model built on everyday consumables and recurring household demand rather than cyclical discretionary spending.

Financially, the competitive信号 is mixed. A net margin of 8.7% is respectable for a low-margin household-products industry, indicating Clorox retains some pricing power and cost discipline despite inflationary input pressure. However, the reported ROE of -1,893.5% is an extreme outlier and does not reflect operating performance alone. A number that negative almost always signals a shrunken or negative shareholders’ equity base—often the result of share buybacks, accumulated losses, or leverage—rather than a conventional profitability shortfall. Clorox does carry a long history of returning cash to shareholders and has used debt, so the ROE figure is best interpreted as a capital-structure artifact rather than evidence that operations are destroying a dollar of equity on each dollar of sales. The practical implication is that the company’s balance-sheet leverage is material: the business still produces cash, but equity holders are sitting on a thin or negative book-value cushion.

Financial posture

Clorox’s current market capitalization is $11.8 billion and its trailing P/E stands at 20.3. That multiple sits roughly in the middle of the defensive-consumer spectrum: not as cheap as deeply out-of-favor staples names, but well below premium-priced growth staples. The valuation appears to price in moderate growth, steady dividends, and some execution risk. The beta of 0.54 confirms a low-volatility profile typical of household-product companies, meaning the stock has historically moved roughly half as much as the broader market during risk-on or risk-off sessions.

The combination of a 20.3 P/E, a 8.7% net margin, and a deeply negative ROE tells a specific story. Profitability at the operating line is intact, yet the equity base is compressed. For a company that has steadily bought back stock and pays a dividend, shareholder returns have historically come from cash distributions more than from equity compounding. Investors evaluating Clorox should separate the income statement, which is still producing earnings, from the balance sheet, which has absorbed years of capital-return programs.

Strategic priorities & outlook

Clorox’s most recent 10-K outlines a clear set of operational priorities. The company is executing its IGNITE strategy around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Management also emphasizes completing and optimizing a new enterprise resource planning (ERP) system and broader digital transformation, with the stated goal of generating long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

The filing flags fiscal 2026 as a difficult year, with organic sales and earnings declining and diluted EPS down 26%. Part of that weakness was attributed to macroeconomic headwinds and ERP transition timing that had pulled some sales into fiscal 2025, making year-over-year comparisons tougher. That timing effect matters for forward modeling: once the ERP comparables roll off, reported growth rates could mechanically improve even if underlying demand is flat.

Portfolio activity is another central theme. In April 2026, Clorox completed the acquisition of GOJO Industries, expanding its health and hygiene portfolio and strengthening its business-to-business presence. The filing points to integrating that acquisition and growing professional and institutional markets as a priority. Separately, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, requiring Clorox to purchase P&G’s 20% interest. After the transaction, Glad retained core intellectual property licenses on a royalty-free basis. That removes a joint-venture overhang but also shifts full ownership economics, for better or worse, onto Clorox.

Customer concentration remains a structural risk. Walmart accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half of consolidated net sales. That leaves pricing power partly dependent on a handful of retail buyers and makes shelf-space negotiations a recurring strategic battle.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox’s macro exposure is defensive but not zero. Demand for bleach, trash bags, cat litter, and salad dressing tends to be non-discretionary, which supports stable volumes through economic cycles. Still, the industry is exposed to rising input costs—resins, packaging, chemicals, transportation, and agricultural commodities—any of which can compress margins if price hikes lag cost increases.

Trade policy and currency are relevant as well. Raw-material imports and finished-goods exports across nearly 95 markets create foreign-exchange translation risk. Tariffs on plastics or chemicals can flow directly into cost of goods sold, while a stronger U.S. dollar can dampen the value of overseas revenue. Regulatory risk is another constant: disinfectant claims, environmental packaging mandates, and FDA or EPA oversight on product formulations can force reformulation costs or label changes. Supply-chain concentration—both geographic and customer-specific—can amplify any of these shocks.

Recent developments

Recent headlines have centered on income-oriented positioning and institutional accumulation. On August 31, 2026, defenseworld.net reported that the Canada Pension Plan Investment Board acquired 32,488 shares of Clorox stock. Earlier in the same week, on August 26, 2026, a youtube.com segment titled “3 Cheap Stocks Offering Attractive Income” included Clorox in the discussion. On August 24, 2026, fool.com ran a piece asking, “Should Passive Income Investors Buy Clorox Stock?” and the same day defenseworld.net noted that Barrow Hanley Mewhinney & Strauss LLC acquired 106,377 shares. None of these items contain fundamental earnings news, but the clustering of dividend-focused coverage and pension-fund buying helps explain why the stock has been on income investors’ radar as it hovers below its 50-day EMA.

Earnings behavior & post-earnings drift

Clorox has a solid recent earnings record: over the last eight reported quarters, the company has beaten estimates 6 out of 8 times (75.0% beat rate) with an average earnings surprise of 9.4%. The average five-day post-earnings price move across those quarters is +1.67%, classified as an “up” drift. That pattern suggests that, on average, positive surprises have not been fully priced in by the close of the following session and that follow-on buying often continues through the rest of the week.

The last four quarters show that the relationship between beats and price reaction is not mechanical. The most recent report, on August 3, 2026, delivered EPS of $1.66 against an estimate of $1.64—a modest 1.2% beat—yet the stock rose 6.52% the next day and 9.61% over the following five sessions. By contrast, the April 30, 2026 quarter was a stronger 5.8% beat ($1.64 vs. $1.55) but the stock sold off 9.67% the next day and 4.49% over the next five days, likely because forward guidance or qualitative commentary disappointed. The February 3, 2026 quarter was a 2.8% miss ($1.39 vs. $1.43), yet the stock gained 2.43% the next day and 5.63% over five days, showing that misses can be forgiven if the narrative points to a second-half recovery. Finally, the November 3, 2025 quarter beat by 3.9% ($0.85 vs. $0.818) but drifted 4.08% lower over the following five days.

Looking ahead, Clorox is scheduled to report next on November 3, 2026, after the close, with a consensus EPS estimate of $1.11. That estimate is noticeably lower than the $1.39–$1.66 range of the prior three quarters, so the market appears to be bracing for continued pressure or seasonal timing tied to the fiscal calendar. The current price of $97.68, with an RSI of 37.3 and a 50-day EMA of $101.19, shows a stock that has pulled back toward short-term momentum support.

For a deeper dive into how institutional investors and sell-side analysts are interpreting Clorox's balance sheet, GOJO integration, and the upcoming November 3 earnings report, it is worth reviewing the full institutional verdict rather than relying on price action alone.